Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Forum Health Econ Policy ; 23(2): 1-23, 2020 11 25.
Article in English | MEDLINE | ID: mdl-33984886

ABSTRACT

OBJECTIVES: Quantify the value of functional status (FS) improvements consistent in magnitude with improvements due to levodopa-carbidopa intestinal gel (LCIG) treatment, among the advanced Parkinson's disease (APD) population. METHODS: The Health Economic Medical Innovation Simulation (THEMIS), a microsimulation that estimates future health conditions and medical spending, was used to quantify the health and cost burden of disability among the APD population, and the value of quality-adjusted life-years gained from FS improvement due to LCIG treatment compared to standard of care (SoC). A US-representative Parkinson's disease (PD)-comparable cohort was constructed in THEMIS based on observed PD patient characteristics in a nationally representative dataset. APD was defined from the literature and clinical expert input. The PD and APD cohorts were followed from 2010 over their remaining lifetimes. All individuals were ages 65 and over at the start of the simulation. To estimate the value of FS improvement due to LCIG treatment, decreases in activities of daily living (ADL) limitations caused by LCIG treatment were calculated using data from a randomized, controlled, double-blind, double-dummy clinical trial and applied to the APD population in THEMIS. RESULTS: Total burden of disability associated with APD was $17.7 billion (B). From clinical trial data, LCIG treatment versus SoC lowers the odds of difficulties in walking, dressing, and bathing by 76%, 42% and 39%, respectively. Among the APD population, these reductions generated $2.6B in value to patients and cost savings to payers. The added value was 15% of the burden of disability associated with APD and offsets 15% of the cost of LCIG treatment. CONCLUSIONS: FS improvements, consistent with improvements due to LCIG treatment, in the APD population created health benefits and reduced healthcare costs in the US.


Subject(s)
Activities of Daily Living/psychology , Carbidopa/standards , Levodopa/standards , Parkinson Disease/complications , Parkinson Disease/drug therapy , Social Values , Aged , Aged, 80 and over , Antiparkinson Agents/pharmacology , Antiparkinson Agents/standards , Carbidopa/pharmacology , Drug Combinations , Female , Gels/pharmacology , Gels/standards , Gels/therapeutic use , Humans , Levodopa/pharmacology , Male , Parkinson Disease/psychology
2.
J Med Econ ; 23(3): 297-307, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31779508

ABSTRACT

Aims: To estimate the relationship between functional status (FS) impairment and nursing home admission (NHA) risk in Parkinson's disease (PD) patients, and quantify the effect of advanced PD (APD) treatment on NHA risk relative to standard of care (SoC).Materials and methods: PD patients were identified in the Medicare Current Beneficiary Survey (MCBS) (1992-2010). A working definition based on the literature and clinical expert input determined APD status. A logit model estimated the relationship between FS impairment and NHA risk. The effect of levodopa-carbidopa intestinal gel (LCIG) on NHA risk relative to SoC was simulated using clinical trial data (control: optimized oral levodopa-carbidopa IR, ClinicalTrials.gov NCT00660387 and NCT0357994).Results: Non-advanced PD and APD significantly increased NHA risk when controlling for demographics (p < 0.01). APD status was no longer significant after controlling for FS limitations, implying that FS limitations explain the increased NHA risk in APD patients. Reduced impairment in FS in patients with APD treated with LCIG reduced risk of NHA by 13.5% relative to SoC.Limitations: This study applies clinical trial results to real-world data. LCIG treatment might have a different effect on NHA risk for the nationally representative population than the effect measured in the trial. Both data sources employ different instruments to measure FS, instrument wording and study follow-up differed, which might bias our estimates. Finally, there lacks consensus on a definition of APD. The prevalence of APD in this study is high, perhaps due to the specific definition used.Conclusions: Patients with APD experience a higher risk in NHA than those with non-advanced disease. This increased risk in NHA in patients with APD is explained by greater limitations in FS. The relative reduction in risk of NHA for the APD population treated with LCIG is quantitatively similar to doubling Medicaid home care services.


Subject(s)
Antiparkinson Agents/therapeutic use , Carbidopa/therapeutic use , Homes for the Aged/statistics & numerical data , Levodopa/therapeutic use , Nursing Homes/statistics & numerical data , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Activities of Daily Living , Aged , Aged, 80 and over , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/adverse effects , Carbidopa/administration & dosage , Carbidopa/adverse effects , Double-Blind Method , Drug Combinations , Female , Gels , Humans , Levodopa/administration & dosage , Levodopa/adverse effects , Male , Medicare/statistics & numerical data , Monte Carlo Method , Physical Functional Performance , Severity of Illness Index , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...